Search

Background: Psoriatic arthritis (PsA), a chronic rheumatic disease associated with reduced quality of life. Obesity is an important clinical problem which may interfere with loss of functioning and quality of life. Obesity is usually an overlooked entity in patients with PsA. Several studies were invastigated prevalence and the impact of obesity on disease activity in patients with PsA, however relationship between psychological status and quality of life have not been evaluated comparatively. Objectives: To assess the impact of obesity on quality of life, psychological status and clinical parameters in patients with PsA. Methods: Patients with PsA were recruited who met CASPAR classification criteria enrolled by Turkish League Against Rheumatism-NETWORK (TLAR-NETWORK) derived from 24 different centers of our country.Patients with BMI ≥30 kg/m2 were considered obese. Differences among patients with or without obesity were assessed.VAS fatigue, psychological status and health related quality of life measures [SF-36; HAQ; Psoriatic arthritis quality of life (PsAQoL); Hospital Anxiety and Depresson Scale], FACIT-Fatigue, DAS28, BASDAI, BASFI, BASMI, Maastrich Ankylosing Spondylitis Enthesitis Score (MASES) and Psoriasis area severity index (PASI) scores were compered between this groups. Results: A total 1130 patients with PsA (36.0% male, 64.0% female) included in this study. In this cohort 37.6% obese and 62.4% non-obese. The presence of peripheral arthritis, enthesitis, dactylitis, uveitis and spine involvement, PASI scores as well as MASES scores were quite similar between patients with and without obesity. Obese patients had significantly higher scores in VAS fatigue and disease activity, poorer QoL and physical functions compared to non-obese patients (p Conclusion: Obesity associated with the risk of depression and anxiety, fatigue, poorer QoL and higher disease activity.These findings suggest that obesity should be considered while assessing patients with PsA. References [1] Li W,Han J,Qureshi AA.Obesity and risk of incident psoriatic arthritis in US women.Ann Rheum Dis.2012Aug;71(8):1267-72. [2] Klingberg E,Bilberg A,Bjorkman S, et al.Weight loss improves disease activity in patients with psoriatic arthritis and obesity:an interventional study.Arthritis Res Ther.2019Jan11;21(1):17 Disclosure of Interests: Kevser Gok: None declared, Kemal Nas: None declared, Erkan Kilic: None declared, Betul Sargin: None declared, Sevtap Acer Kasman: None declared, Hakan Alkan: None declared, Nilay Sahin: None declared, Gizem Cengiz: None declared, Nihan Cuzdan: None declared, Ilknur Albayrak Gezer: None declared, Dilek Keskin: None declared, Cevriye Mulkoglu: None declared, Hatice Resorku: None declared, Ismihan Sunar: None declared, Ajda Bal Hasturk: None declared, Mehmet Tuncay Duruoz Grant/research support from: Abvie, Speakers bureau: Novartis, AMGEN, Abdi Ibrahim, Ilko, Okan Kucukakkas: None declared, Ozan Volkan Yurdakul: None declared, Meltem Alkan Melikoglu: None declared, Yildiray Aydin: None declared, Figen Ayhan: None declared, Hatice Bodur: None declared, Mustafa Calis: None declared, Erhan Capkin: None declared, Gul Devrimsel: None declared, SAMI HIZMETLI: None declared, Ayhan Kamanli: None declared, Yasar Keskin: None declared, Hilal Kocabas: None declared, Oznur Kutluk: None declared, Nesrin Sen: None declared, Omer Faruk Sendur: None declared, ibrahim tekeoglu: None declared, Murat Toprak: None declared, Sena Tolu: None declared, Tiraje Tuncer: None declared

Background: Axial Spondyloarthropathies (SpA) are chronic, systemic, inflammatory diseases which affect the axial skeleton, limit chest mobility and cause serious impairments in pulmonary functions. Objectives: In this cross-sectional study, as a new approach; diaphragm thickness is assessed by ultrasound in patients with axial SpA to determine possible relationships with pulmonary functions and disease activity. Methods: 49 axial SpA patients enrolled in the study were assessed by Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Metrology index (BASMI), Erythrocyte Sedimentation Rate (ESR), serum C-Reactive Protein levels (CRP) and chest expansion (cm). 15 patients with lung diseases other than axial SpA pulmonary involvement, neuromuscular diseases, scoliosis and congenital chest deformity were excluded. Dynamic pulmonary function tests (PFT) and 6 min walk (6MW) tests were done and physical activity levels were evaluated by short form International Physical Activity Questionnaire (IPAQ). Diaphragm thickness was measured at end expiration (dtFRC) and deep inspiration (total lung capacity (dtTLC)). Thickness ratio (dtr: dtTLC/dtFRC) and thickness change (dtc: dtTLC-dtFRC) were calculated. Results: The descriptive data of the patients are presented in Table 1. Patients had a moderate disease activity and all the patients were category 1 (inactivity) according to IPAQ. Mean value of dtr and PFT seem to be within normal range according to population studies and dtr was significantly correlated with dynamic pulmonary function tests, yet negatively correlated with ESR (r: -0.466, p: 0.006). There was insignificant negative correlation with age, disease duration, BASDAI, BASFI, and BASMI. Conclusion: To the best of our knowledge, this is the first study evaluating the relation between diaphragm thickness and pulmonary functions with disease activity. Even though, there was no limitation in PFT and expected values were obtained in dtr, the negative correlation with ESR makes us think about the possible effect of disease activity on dtr. With these preliminary results, it is early to conclude, but dtr assessment may be complementary to PFT and early measures to improve diaphragm function with specific exercises should be implemented in patients with axial SpA. Reference [1] Carrillo-Esper R, Perez-Calatayud AA, Arch-Tirado E, Diaz-Carrillo MA, Garrido-Aguirre E4, Tapia-Velazco R, Pena-Perez CA, Espinoza-de Los Monteros I, Meza-Marquez JM, Flores-Rivera OI, Zepeda-Mendoza AD, de la Torre-Leon T. Standardization of Sonographic Diaphragm Thickness Evaluations in Healthy Volunteers Respir Care 2016;61(7):920-4 Disclosure of Interests: None declared

Background Psoriatic arthritis (PsA) is an immune-mediated disease affecting skin, joints, entheses, spine, and the vasculature [1,2]. Increased inflammatory mediators are held responsible for impacts on the skin and musculoskeletal system as well as comorbid situations including cardiovascular disease (CVD) and metabolic syndrome [3]. PTX 3 is an acute phase reactant that has prognostic value for rheumatoid arthritis (RA), vasculitis, and psoriasis that also stands out as a novel biomarker for CVD in new researches [4]. Objectives This study aims to assess the association between PTX 3 levels, disease activity and CVD risk in patients with PsA. Methods A total of 38 PsA patients applying to Ankara University Faculty of Medicine, Rheumatology Polyclinic and 32 age and sex-matched controls were enrolled in the study. tender and swollen joint counts, patient9s and doctor9s global assesment on VAS, ESR, CRP, fasting insulin, fasting glucose, total cholesterol, HDL, and LDL were noted. Also body mass index (BMI) and HOMA-IR score were calculated. Carotid intima media thickness (cIMT) was bilaterally assessed by Doppler ultrasound. Results The mean age was 49.5 in patients and 48.9 in controls. Sixty percent of the patients and 50% of controls were female. Of the patients, 15 (39%) used DMARD monotherapy, 8 (21%) used DMARD combination therapies, and 15 (39%) used anti TNF therapies. There was no statistically significant difference between groups in terms of hypertension, LDL levels, and smoking status (p:0.775, p:0.228, p:0.136 respectively). PsA patients had significantly higher BMI scores (p:0.03). Insulin levels and HOMA-IR scores were significantly higher among PsA patients compared to controls (p:0.001, p:0.005). There was statistically significant difference between groups in terms of PTX 3 (p Conclusions Elevated levels of PTX 3 may be associated with cardiovascular involvement in PsA patients independent from the disease activity. This marker might be used for risk prediction for CVD or may represent a target for new therapies. References Braun J. New targets in psoriatic arthritis. Rheumatology (Oxford). 2016 Dec;55(suppl 2). Egeberg A. Psoriasis and comorbidities. Epidemiological studies. Dan Med J.2016 Feb;63(2). Rutter MK, Kane K, Lunt M, et al. Primary care based screening for cardiovascular risk factors in patients with psoriasis. Br J Dermatol. 2016 Mar 1. Inoue K, Kodama T, Daida H. Pentraxin 3: a novel biomarker for inflammatory cardiovascular disease Int J Vasc Med. 2012;2012:657025. Disclosure of Interest None declared